Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
DNB Asset Management AS Sells 2,663 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
11:46am, Thursday, 23'rd Apr 2020
DNB Asset Management AS lessened its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 16.8% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 13,226
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by BidaskClub
09:42am, Thursday, 23'rd Apr 2020
Ionis Pharmaceuticals (NASDAQ:IONS) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Thursday, BidAskClub reports. Several other broke
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
03:08pm, Wednesday, 22'nd Apr 2020
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
03:08pm, Wednesday, 22'nd Apr 2020
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
4 Monster Stocks in the Making
11:45am, Wednesday, 22'nd Apr 2020
A handful of companies seem immune to fallout from the COVID-19 pandemic. Some may even benefit from it.
Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
11:05am, Wednesday, 22'nd Apr 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 6th at 11:30 a.m. Eastern Time to discuss its first quarter 2020 financial results and rep
Grab 5 Top Stocks With Strong Earnings Beat Prospects
11:09am, Tuesday, 21'st Apr 2020
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
Grab 5 Top Stocks With Strong Earnings Beat Prospects
11:09am, Tuesday, 21'st Apr 2020
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
11:00am, Tuesday, 21'st Apr 2020
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, May 5 at 4:30 p.m. Eastern Time to discuss its
Needham Reiterates a Buy Rating on Esperion (ESPR)
07:53pm, Monday, 20'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on Esperion (ESPR) today and set a price target of $158.00. The company's shares closed last Monday at
Needham Reiterates a Buy Rating on Esperion (ESPR)
07:53pm, Monday, 20'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target
Exelixis (EXEL) Gets a Buy Rating from Needham
05:38pm, Monday, 20'th Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Exelixis (EXEL) today and set a price target of $33.00. The company's shares closed last Monday at
Exelixis (EXEL) Gets a Buy Rating from Needham
05:38pm, Monday, 20'th Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target
Roche completes enrollment in study of tominersen in Huntington's disease
11:38am, Monday, 20'th Apr 2020
Ionis Pharmaceuticals (NASDAQ:IONS) announces that exclusive licensee Roche (OTCQX:RHHBY) has completed the enrollment of 791 subjects in a Phase 3 clinical trial, GENERATION HD1, evaluating antisense
Ionis: Roche completes enrollment in Phase 3 GENERATION HD1 study IONS;RHHBY
11:26am, Monday, 20'th Apr 2020
Ionis: Roche completes enrollment in Phase 3 GENERATION HD1 study IONS RHHBY
